Hepatitis D Latest Advances

Find the Latest Research About Hepatitis D

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3424 publications

Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis.

Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis.

Journal: Swiss medical weekly

Published: April 10, 2026

HDV sensing drives USP18-mediated refractoriness to IFN-α response, sparing IFN-β/λ in hepatocytes.

HDV sensing drives USP18-mediated refractoriness to IFN-α response, sparing IFN-β/λ in hepatocytes.

Journal: Antiviral research

Published: February 20, 2026

Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release.

Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release.

Journal: bioRxiv : the preprint server for biology

Published: February 12, 2026

Correction to: Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D).

Correction to: Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D).

Journal: Open forum infectious diseases

Published: February 05, 2026

Consensus document on the diagnosis, management, and treatment of chronic hepatitis B virus and hepatitis D virus infection in Spain.

Consensus document on the diagnosis, management, and treatment of chronic hepatitis B virus and hepatitis D virus infection in Spain.

Journal: Gastroenterologia y hepatologia

Published: February 04, 2026

Hepatitis D Virus Pathogenesis: A Sense of Complications.

Hepatitis D Virus Pathogenesis: A Sense of Complications.

Journal: Viruses

Published: January 30, 2026

Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models.

Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models.

Journal: Antimicrobial agents and chemotherapy

Published: January 26, 2026

Shedding new light on the chicken-and-egg dilemma of hepatitis delta virus (HDV) replication initiation.

Shedding new light on the chicken-and-egg dilemma of hepatitis delta virus (HDV) replication initiation.

Journal: Hepatology (Baltimore, Md.)

Published: January 23, 2026

IL-37 and IL-36 Cytokine Profiles in Chronic Hepatitis Delta During Bulevirtide Therapy.

IL-37 and IL-36 Cytokine Profiles in Chronic Hepatitis Delta During Bulevirtide Therapy.

Journal: Pathogens (Basel, Switzerland)

Published: January 22, 2026

Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.

Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.

Journal: Diseases (Basel, Switzerland)

Published: January 21, 2026

A New Therapeutic Broadcast on Hepatitis D, a Satellite Virus.

A New Therapeutic Broadcast on Hepatitis D, a Satellite Virus.

Journal: The New England journal of medicine

Published: January 21, 2026

Impact of sensitivity difference between two widely used HDV RNA quantification assays on the management of HDV-infected patients treated with bulevirtide.

Impact of sensitivity difference between two widely used HDV RNA quantification assays on the management of HDV-infected patients treated with bulevirtide.

Journal: Journal of virological methods

Published: January 12, 2026

Showing 1-12 of 3,424

Last Updated: 04/28/2026